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Objectives We sought to assess the spectrum and outcome of young long QT syndrome (LQTS) patients, addressing treat-
ment including device indications, risks, and benefits.
Background Long QT syndrome has a phenotype ranging from asymptomatic electrocardiogram (ECG) abnormalities to sud-
den death. Treatments include beta-blockers and device implantation in high-risk individuals. Despite genetic
testing, accurate risk stratification remains challenging.
Methods A database search at 3 institutions identified all pediatric LQTS patients. Records were reviewed for demograph-
ics, criteria for diagnosis, treatment, follow-up, and ECG and device data.
Results We identified 128 patients ages 8.0  5.4 years with QTc of 487  39 ms and follow-up of 4.4  3.5 years.
Most were diagnosed because of an abnormal ECG in a patient with a family history (53%). Genetic mutations
were identified in 51 patients. Beta-blockers were used in 126 (98%) and pacemaker/implantable cardioverter-
defibrillator implantation in 27 (21%) patients, usually because of symptoms despite use of beta-blockers. Pac-
ing was common; 22% received an appropriate shock but device-related re-intervention occurred in 48%. Device
patients had longer QTc intervals (p  0.03) and more symptoms (p  0.001). No one with an isolated KCNQ1
and all patients with an SCN5A mutation had device implantation. During the study period, there were 2 deaths.
Conclusions Long QT syndrome without symptoms is increasingly recognized as family members are screened. Evaluation of
this minimally symptomatic population offers an evolving understanding of LQTS. Previous studies of highly
symptomatic patients were more worrisome. In the era of genetic testing and device implantation, overall mor-
tality is low with treatment. Device therapy, although effective, is not without complications and should be re-
served for high-risk patients. (J Am Coll Cardiol 2007;50:1335–40) © 2007 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.05.042s
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uong QT syndrome (LQTS) is the prototype channelopa-
hy. With over 600 disease-causing mutations in cardiac ion
hannel genes, LQTS is thought to affect at least 1 in 5,000
eople. The LQTS phenotype is variable, ranging from
symptomatic electrocardiogram (ECG) repolarization
See page 1341
bnormalities to sudden death. There are several variables
hat have been associated with a high risk of sudden death,
ncluding young age (1,2), the presence of a sodium channel
utation (SCN5A) (3), a markedly prolonged QT interval
4), the Jervell and Lange-Nielsen genotype (5), and other
ompound mutations (6). The ability to determine the
rom the *University of Utah, Salt Lake City, Utah; †University of British Columbia,
ancouver, British Columbia, Canada; and the ‡Phoenix Children’s Hospital and
rizona Pediatric Consults/Pediatrix, Phoenix, Arizona.v
Manuscript received March 16, 2007; revised manuscript received April 25, 2007,
ccepted May 5, 2007.pecific genetic abnormality has permitted correlations with
henotype that may improve risk stratification. Yet, at
resent, genetic testing is largely limited to research proto-
ols and a single commercial laboratory. Despite an increase
n genetic testing, precise risk stratification is not possible.
As the awareness of LQTS increases, more cases are
dentified; many asymptomatic cases are brought to medical
ttention as the result of family screening, further confound-
ng risk stratification. The variables previously described to
e associated with high risk may not, therefore, apply to this
rowing population.
Although genetic testing and our understanding of the
echanism of LQTS have increased dramatically, the
herapy in LQTS has remained empiric. Beta-blockers form
he mainstay of therapy in all patients, whereas high-risk
atients now receive implantable cardioverter-defibrillators
ICDs). Decisions concerning appropriate therapy must be
ndertaken with a comprehensive understanding of the
ariable phenotype and genotype.
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LQTS in Children October 2, 2007:1335–40Young patients with LQTS
are thought to be at greater risk
when compared with adults, and
adolescents represent the highest
risk group (2). As a result, more
aggressive treatment has been
advocated in this population
(7). We set out to evaluate a
large cohort of children with
QTS to better understand LQTS and improve risk
tratification in the era of family screening, genetic
iagnosis, and ICD implantation.
ethods
opulation. After institutional review board approval was
btained from the 3 participating institutions, pediatric
ardiology database searches identified all patients 18 years
f age or younger diagnosed with LQTS from January 1990
o June 2006. Demographic data, personal and family
istory, ECG data, and genetic diagnosis, when available,
ere ascertained. Follow-up was closed on August 1, 2006,
r at the patient’s last recorded cardiology clinic visit. Five
atients had not attended follow-up appointments in more
han 2 years and could not be contacted concerning their
ondition. Although their medication compliance and clin-
cal status are unknown, the social security death records
ere searched to confirm that there were no deaths reported
n this group. The initial baseline, unpaced 12-lead ECG
efore therapy, was used to calculate the corrected QT
nterval using the formula of Bazett (8). Genetic analyses
ere performed in established laboratories, including both
esearch and commercial facilities. Patients were frequently
ssessed with exercise testing, although this was not system-
tic. The use of epinephrine challenge was uncommon.
The proband was defined as the first patient in a family
iagnosed with LQTS; the term nonproband was used to
escribe all other relatives regardless of symptoms or health
tatus.
evice patients. Device implantation indications, pro-
ramming data, antitachycardia therapies, complications,
nd revisions were noted. The percentage of time paced and
ppropriate and inappropriate ICD discharges were re-
iewed. Device patients were compared with those without
evices.
tatistical analyses. Quantitative variables are presented as
ean  SD and categorical variables as percentages. Stu-
ent t test was used to compare continuous data and the
hi-square or Fisher exact test for categorical data. Kaplan-
eier analysis was used to assess survival with differences
etween groups determined by log-rank test. A p value of
0.05 was considered significant.
esults
opulation. A total of 128 patients were identified with
Abbreviations
and Acronyms
ECG  electrocardiogram
ICD  implantable
cardioverter-defibrillator
LQTS  long QT syndrome
TdP  torsades de pointesQTS from 91 families. These included 52 (41%) probandsnd 76 nonprobands. There were 66 (52%) female patients.
he mean age at diagnosis was 8.0  5.4 years. The QTc
as 487 39 ms, and the length of follow-up was 4.4 3.5
ears. Probands had significantly longer QTc intervals
495  42 ms) when compared with nonprobands (481 
7 ms, p  0.04) and were older at diagnosis (9.6  5.1
ears vs. 6.8  5.4 years, p  0.003). The most common
eason for diagnosis was an abnormal screening ECG in the
etting of a positive family history, as shown in Figure 1.
even patients who presented for evaluation acknowledged
family history of LQTS but did not seek medical attention
ntil they experienced syncope. They were included in the
onproband group.
enetic testing. Genetic testing has been performed in 72
atients (56%) and has identified an abnormality in 51
40%) patients (Fig. 2). There were 3 patients with genetic
est results that were negative for known mutations, and test
esults are pending in 18. A KCNQ1 mutation was the most
ommon defect identified. A single proband with multiple
yncopal events and a markedly prolonged QTc interval was
dentified as a compound heterozygote with both KCNQ1
nd SCN5A mutations. In those with positive genetic test
esults, there were 6 with borderline (450 to 460 ms) QTc
rolongation and 1 with a normal QTc at 430 ms; none had
n SCN5A mutation.
herapy. In this population, 126 (98%) patients were on
eta-blocker therapy. One patient was diagnosed after her
udden death when a prior ECG and family history were
eviewed. A second patient with an SCN5A mutation and
n ICD was not treated with a beta-blocker. Beta-blocker
herapy included nadolol in most patients, with propranolol
nd atenolol used less often. Because of described treatment
ailures (9), the investigators have decreased the use of
tenolol. Adequacy of beta-blockade was routinely assessed
ith 12-lead ECG, Holter monitoring in young patients,
Figure 1 Reason for Diagnosis of LQTS
The diagnosis of long QT syndrome (LQTS) was most often made because of a
family history and an abnormal electrocardiogram (ECG) obtained as a screen-
ing tool. As shown here in blue, 53% of our patients were diagnosed as a
result of family screening. In red are the patients diagnosed after presentation
with syncope. Sudden death or resuscitated sudden death was present in only
3% of patients, and 17% were diagnosed because of an abnormal ECG in the
absence of symptoms or a family history of LQTS.
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October 2, 2007:1335–40 LQTS in Childrennd exercise testing in older children. Both mexiletine and a
eta-blocker were used in 2 patients.
evice therapy. Implantation indications varied little be-
ween centers (Fig. 3). All 3 centers recommended implan-
ation for documented ventricular tachycardia or torsades de
ointes (TdP), syncope despite beta-blocker therapy, pre-
entation with resuscitated sudden death, and identification
f an SCN5A mutation. Although 3 patients had ICDs
mplanted because of a family history of sudden death, there
as not a consensus among participating electrophysiolo-
ists concerning this indication.
A total of 27 patients had devices placed, including 8 with
picardial (4 pacemakers, 4 ICDs) and 19 with endocardial
ystems (4 pacemakers, 15 ICDs). The age at implantation
f a device was 9.4  5.4 years. Children with epicardial
evices were 5 years of age or younger. There were 20 (74%)
atients with dual-chamber devices and 7 (26%) with
ingle-chamber ventricular devices. Device programming
as done according to 2 strategies: 1) the shock box
pproach, single-chamber demand pacing at a lower rate of
0 to 50 beats/min (8 patients, 30%); or 2) the rate support
pproach, in which a higher-than-age-appropriate resting
eart rate was chosen for the prevention of pauses (19
atients, 70%).
Indications for pacemaker implantation were syncope
espite beta-blocker therapy (6 patients), ventricular ar-
hythmias despite beta-blocker therapy (1 patient), and 2:1
trioventricular block (1 patient) (Fig. 3). Four patients with
acemakers underwent a change to an ICD: 3 had docu-
ented ventricular arrhythmias despite pacing, and 1 up-
rade was performed at the time of generator change in a
atient with medication noncompliance. An ICD was the
nitial device therapy in 19 patients. Therefore, a total of 23
atients ultimately had ICD implantation, whereas 4 re-
ained with a pacemaker.
Based on device interrogation data, 63% of patients had
ore than 30% of heart beats paced. There were 5 patients
Figure 2 Genetic Diagnoses in Those
With Available Genetic Data
Genetic testing results are known in 51 patients. The KCNQ1 mutation was
most common. There was a single patient with both the SCN5A mutation and
the KCNQ1 mutation who is listed in both groups.ho had at least 1 appropriate ICD discharge and 4 patientsith at least 1 inappropriate ICD discharge, including 2
atients with both. Appropriate ICD discharges occurred
uring exertion in 3 patients, including 2 brothers who were
ghting with one another at the time of their nearly
imultaneous shocks. Although these 2 have had multiple
ppropriate shocks during periods of exercise, no patient has
ad a classic electrical storm with multiple consecutive
hocks. The other 2 patients with appropriate discharges
ad events during rest. Thus, 5 of 23 (22%) patients have
eceived appropriate ICD therapy, with a mean time to first
ppropriate shock of 18  22 months.
When the ICD patients with an appropriate shock were
ompared with those without, there was no difference in
ge, QTc interval, length of follow-up, or length of time
ith a device. Only 2 of the patients with appropriate
hocks have been gene tested, and both have a KCNH2
utation. Conversely, 4 patients with this mutation have
ot had appropriate shocks and no one with a known
CN5A mutation has had an appropriate ICD discharge.
Of the 13 patients with a device implanted for syncope
espite beta-blocker therapy, 9 had no further symptoms, 3
ad appropriate ICD discharges, and 1 with a pacemaker
ad continued syncope and underwent upgrade to an ICD.
he has had no ICD discharges or further syncope (Fig. 4).
here were 4 patients who underwent device implantation
ecause of documented ventricular arrhythmias (2 ICDs, 2
acemakers). In this group, 1 ICD patient had no further
ymptoms and the other had an appropriate ICD discharge.
ne patient with a pacemaker underwent a change to an
CD after a documented ventricular fibrillation arrest. The
Figure 3 Indications for Device Implantation
The most common indication for device implantation was syncope despite
beta-blocker therapy. There were 13 patients in this group. Devices were
placed in 4 patients with documented torsades de pointes (TdP) or ventricular
tachycardia (VT) and in 3 who presented with resuscitated sudden death. A
family history of sudden death caused by long QT syndrome (LQTS) was the
sole indication in 3 additional patients. A pacemaker was placed in an infant
with LQTS and 2:1 atrioventricular block (AVB), and an implantable cardioverter-
defibrillator (ICD) was placed in an asymptomatic patient with an SCN5A muta-
tion. A device was placed in 1 patient with syncope and a QTc interval of 600
ms who was later identified as a compound heterozygote having both SCN5A
and KCNQ1 mutations. BB  beta-blockers; FH  positive family history of
long QT syndrome; SD  sudden death.
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LQTS in Children October 2, 2007:1335–40ther pacemaker patient died suddenly in infancy on beta-
locker therapy before the accepted use of ICDs in small
nfants. Of the 3 patients with ICD placement after
resentation with resuscitated sudden death, none had
urther symptoms or ICD shocks although arrhythmias
ere documented. There were 2 patients in whom ICD
nterrogation disclosed a spontaneously terminating ventric-
lar tachycardia episode.
Inappropriate ICD shocks were seen in 4 of 23 (17%)
atients: 3 for sinus tachycardia during exertion, and 1, a
hild with an SCN5A mutation, had a shock with atrial
brillation. All were receiving beta-blockers and all had
ual-chamber devices; no inappropriate shocks were seen
n the single-chamber device patients. There were no
nappropriate shocks because of lead fracture or T-wave
versensing.
Over a mean follow-up of 3.5  2.3 years, 13 patients
48%) required re-intervention related to their device. This
ncludes device recalls in 5 (2 with associated upgrade to
ual chamber device), upgrade from a pacemaker to an ICD
n 4, and a single re-intervention each for battery depletion,
ead repositioning, lead fracture, and infection.
Device patients had longer corrected QT intervals (p 
.03) and were more likely to have symptoms than the
roup without devices (p  0.001) (Table 1). Interestingly,
atients with devices were not more likely to be probands,
nd their survival did not differ from that of patients without
evices (Fig. 5).
No patient with a known, isolated KCNQ1 mutation had
n ICD (Fig. 6), but all 5 patients known to have an
Death 1
No further
symptoms 4
Pacemaker
patients 8
IC
u
VT/VF 3
medication noncompliance 1
Figure 4 Outcomes in Pacemaker and ICD Patients
There were 8 patients in whom a pacemaker was initially implanted. In this group
defibrillator (ICD), 3 after documented ventricular tachycardia (VT) or ventricular fib
time of a generator change because of concerns about compliance with beta-block
device therapy. Appropriate shocks have occurred in 5 patients, and inappropriate
omparison of Long QT Syndromeatients With and Without a Device
Table 1 Comparison of Long QT SyndromePatients With and Without a Device
Device No Device p Value
Age at diagnosis (yrs) 7.3 5.7 8.1 5.3 NS
Length of follow-up (yrs) 4.8 3.8 4.1 3.3 NS
QTc (ms) 502 53 483 33 0.03
() syncope (%) 81 37 0.001
() proband (%) 52 36 NS() family history (%) 73 75 NSCN5A mutation did. There was no association between
evice placement and implementation of genetic testing.
In our patients there were 2 deaths (2%). A young woman
ied before diagnosis and without treatment. Review of her
revious ECG and evaluation and genetic testing of family
embers confirmed a KCNQ1 mutation. The other death
as an infant with 2:1 AV block who died suddenly despite
pacemaker and beta-blocker therapy. Neither death oc-
urred during exertion.
iscussion
ong QT syndrome is a genotypically and phenotypically
eterogeneous disease. Despite the wide range of clinical
anifestations, therapeutic options are limited and include
eta-blockade, mexiletine, pacemakers, and ICD implanta-
ion in addition to sports restrictions and avoidance of
edications that lengthen repolarization.
Decisions concerning candidacy for device therapy have
ot been standardized (10) and remain medically and
sychologically challenging in young patients (11,12).
ICD
patients 19
4
3
1
Appropriate
Shock 5
o
ock 16
Inappropriate
Shock 4
was 1 death, and 4 patients underwent upgrade to an implantable cardioverter-
n (VF). A single asymptomatic patient underwent an upgrade to an ICD at the
rapy. There were 19 patients who underwent an ICD implantation as initial
s in 4 patients. Sixteen ICD patients have not had a shock.
Figure 5 Kaplan-Meier Survival Curve of
Patients With and Without a Device
A shown in this Kaplan-Meier graph, survival was not different in patients
with and without devices. The 15-year survival was 90% in both groups.D
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October 2, 2007:1335–40 LQTS in Childrenechnical advances such as smaller generator size and
ubcutaneous high-voltage electrodes have helped decrease
he role of size in the selection of device therapy. Although
se of a pacemaker in smaller children with later upgrade to
n ICD proved an effective option in some of our patients,
he sudden death of 1 infant underscores the possible
onsequences of pacing without an ICD. The decision to
se device therapy in an infant is an amalgam of 3
omponents: patient size, perceived risk of events, and
echnical limitations. Once the technical disadvantages of
n ICD are overcome, this therapy should be selected over
acing. The rate of appropriate shocks (22%) and the use of
radycardia functions of the devices show their value for
elected LQTS patients.
Growing children, in whom a lifetime of device therapy is
equired, are at greater risk for device-related complications.
aster sinus rates increase the risk of inappropriate ICD
ischarges (12,13) and associated medical and psychological
mpact. The frequency of re-intervention and the inappro-
riate shocks are persuasive evidence against a more aggres-
ive implanting approach.
Patients in our series with devices were genetically dis-
inct: no patient identified with an isolated KCNQ1 muta-
ion had a device, whereas all patients with a known
CN5A mutation have ICDs. Selection of appropriate
evice recipients remains challenging but should be limited
o high-risk patients unlikely to respond to or having failed
eta-blocker therapy.
Causes of individual clinical events are incompletely
nderstood and vary with genotype (3,6). Although young
atients are thought to have an increased risk of sudden
eath (2), we found that mortality was low in this cohort.
ur study group is unique in that it represents a young
opulation, often identified in the absence of symptoms.
arly identification, intervention with beta-blocker therapy,
Figure 6 Genetic Diagnoses
in Patients With and Without a Device
Genetic testing results are known in 51 patients, and the KCNQ1 mutation is
the most common finding. A single patient was identified with a compound
mutation of KCNQ1 and SCN5A and is represented in both columns. This is
the only patient with a device in the group with a known KCNQ1 mutation.nd necessary restrictions may underlie the low mortality. encreasing awareness of medication interactions may be a
rotective factor in the current era. Use of beta-blocker
herapy has been associated with a reduced risk of sudden
eath and aborted sudden death in high-risk individuals (2),
ut has not proven as effective in eliminating cardiac events
n patients with LQT2 and LQT3 (14). Beta-blocker
herapy in our population, with a prevalence of LQT1, may
ave influenced mortality.
Family history in LQTS, although important for establish-
ng the diagnosis, is not helpful for risk stratification (15).
lthough the reasons behind the variable penetrance remain
ncertain, it is becoming clear that genotype-positive relatives
ay have disparate clinical outcomes. Treatment of patients in
he absence of symptoms may in some patients reduce the risk
f symptom development while committing others to a life-
ime of unnecessary therapy.
Clinical practice patterns for the management of patients
ith LQTS are diverse and in constant evolution. Although
his was a retrospective study, there was remarkable uniformity
mong participating centers concerning the indications for
evice implantation. All 3 centers recommended device im-
lantation in patients with documented ventricular tachycardia
r TdP, syncope despite beta-blocker therapy, resuscitated
udden death, or a known SCN5A mutation. It is unlikely that
here will be a future prospective trial of the management of
QTS in children. Thus, this multicenter design is a template
or safe clinical practice. The management patterns of the
enters participating in this series seemed to strike a reasonable
alance between adverse effects of the various therapies and an
xcellent overall outcome.
tudy limitations. Not all patients have completed genetic
esting; diagnosis was made clinically by a pediatric electro-
hysiologist. In these patients the DNA samples were
ubmitted to research laboratories, with lower costs but an
ntirely undefined timeline for results. Our population
iffers somewhat from the recent reports concerning genetic
iagnoses because a substantially greater number had a
CNQ1 mutation (16), possibly reflecting participation
rom the group in Utah and the founder effect in this
opulation. These patients are the most sensitive to beta-
locker therapy, and this may have decreased overall mor-
ality. Additionally, a cluster of device recalls and advisories
ccurred during the period under study, increasing the rate
f device re-intervention in a way that may not be main-
ained in future years, but underscoring the concern that this
herapy is not without unexpected risk. The small number
f deaths in this cohort weakens any comparison of mor-
ality between patient subgroups.
onclusions
ong QT syndrome is increasingly recognized in the
bsence of symptoms as family members are screened by
CG and genetic testing. Evaluation of the asymptomatic
r minimally symptomatic but treated population offers an
volving understanding of this disease in the young. Past
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LQTS in Children October 2, 2007:1335–40valuations of highly symptomatic patients, often the pro-
ands, yielded a more worrisome picture of this disease. In
he era of genetic testing and device implantation, overall
ortality is low in young patients with LQTS with treat-
ent. Clinical practice patterns by 5 pediatric electrophysi-
logists at 3 separate institutions still regard an SCN5A
utation as a cohort that warrants ICD implantation
rrespective of symptoms. Conversely, the genetic confirma-
ion of a KCNQ1 mutation is reassuring. Patients in this
roup have a low mortality and are unlikely to need ICD
mplantation as long as there is compliance with necessary
estrictions and beta-blocker therapy.
eprint requests and correspondence: Dr. Susan P. Etheridge,
00 North Medical Drive, Salt Lake City, Utah 84113. E-mail:
csether@ihc.com.
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